Printer Friendly

Mylan unveils generic Avodart Capsules for treating benign prostatic hyperplasia in men in the US.

M2 PHARMA-June 27, 2016-Mylan unveils generic Avodart Capsules for treating benign prostatic hyperplasia in men in the US

(C)2016 M2 COMMUNICATIONS

Pharmaceutical company Mylan NV(Nasdaq:MYL) TASE:MYL) revealed on Friday the availability of Dutasteride Capsules, 0.5 mg in the US market.

The company said Dutasteride Capsules, 0.5 mg is the generic version of GlaxoSmithKline's Avodart Capsules.

In conjunction, the company has receivred final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dutasteride Capsules, 0.5 mg.

Dutasteride Capsules are reportedly indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.

For the 12 months ending 30 April 2016, Dutasteride Capsules, 0.5 mg, had US sales of approximately USD297.2m, according to IMS Health.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 27, 2016
Words:185
Previous Article:Jazz Pharmaceuticals reports expiration of HSR Waiting Period for planned acquisition of Celator Pharmaceuticals.
Next Article:Vitrolife Launches EmbryoScope+ Time-Lapse System.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters